| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8647308 | Multiple Sclerosis and Related Disorders | 2018 | 4 Pages |
Abstract
In patients treated with natalizumab, shifting from SID to EID has no negative effect on efficacy as evidenced by relapse rate, disability progression and MRI activity.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Genetics
Authors
Bassem I. Yamout, Mohamad Ali Sahraian, Nabil El Ayoubi, Hani Tamim, Johnny Nicolas, Samia J. Khoury, Maya M Zeineddine,